Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Potential of NF-κB Inhibition in the Treatment of Chronic Lymphocytic Leukemia

Carl-Philipp Simon-Gabriel, Marco Benkißer-Petersen, Kazuo Umezawa, Katja Zirlik

Blood (2014) 124 (21): 3625.

https://doi.org/10.1182/blood.V124.21.3625.3625

Published: 2014

Journal Articles

Inhibition of NF-κB Activation Augments the Effect of 5-Azacytidine On Acute Myeloid Leukemia Cell Line

Tomiteru Togano, MD, PhD, Makoto Nakashima, MS, Mariko Watanabe, PhD, Kazuo Umezawa, PhD, Toshiki Watanabe, MD, PhD, Masaaki Higashihara, M.D., PhD., Ryouichi Horie, MD, PhD

Blood (2012) 120 (21): 1369.

https://doi.org/10.1182/blood.V120.21.1369.1369

Published: 2012

Journal Articles

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Eishi Ashihara, MD, PhD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Asumi Yokota, MMSc, Ruriko Tanaka, MMSc, Rina Nagao, Tatsutoshi Nakahata, M.D., Ph.D., Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2166.

https://doi.org/10.1182/blood.V114.22.2166.2166

Published: 2009

Journal Articles

Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis

Eriko Suzuki, Ph.D., Kazuo Umezawa, Ph.D., Gustavo Helguera, PhD, Tracy R Daniels, Ph.D., Gary Schiller, James R. Berenson, MD, Manuel L Penichet, M.D., Ph.D., Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4473.

https://doi.org/10.1182/blood.V112.11.4473.4473

Published: 2008

Journal Articles

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Takashi Ushiki, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Keiko Hodohara, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 3185.

https://doi.org/10.1182/blood.V112.11.3185.3185

Published: 2008

Journal Articles

Tumor Necrosis Factor-α Contributes to Microenvironmental up- Regulation of NF-κB Activity in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Implication for a Novel Therapeutic Target.

Hui-Jen Tsai, MD, Seiichiro Kobayashi, MD, PhD, Kiyoko Itoh, PhD, Takaomi Ishida, PhD, Kazuo Umezawa, PhD, Arinobu Tojo, MD, PhD

Blood (2008) 112 (11): 1912.

https://doi.org/10.1182/blood.V112.11.1912.1912

Published: 2008

Journal Articles

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Mario I. Vega, PhD, Melisa Martinez- Paniagua, Sara Huerta-Yepez, PhD., Eriko Suzuki, Kazuo Umezawa, Kam Yeung, Ph.D., Massimo Libra, Stavroula Baritaki, Michael A. Palladino, PhD, Benjamin Bonavida, PhD

Blood (2008) 112 (11): 4973.

https://doi.org/10.1182/blood.V112.11.4973.4973

Published: 2008

Journal Articles

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Miki Takeuchi, Junya Kuroda, Shinya Kimura, Eishi Ashihara, Kazuo Umezawa, Eiko Yasui, Makoto Kawatani, Hiroyuki Osada, Keiko Hodohara, Yoshihide Fujiyama, Taira Maekawa

Blood (2007) 110 (11): 2931.

https://doi.org/10.1182/blood.V110.11.2931.2931

Published: 2007

Journal Articles

Microenvironmental Up-Regulation of NF-kB Activity Via P65-Dependent and Independent Pathways in a Bioimaging Model of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Hui-Jen Tsai, MD, Seiichiro Kobayashi, M.D., Ph.D., Kiyoko Itoh, Ph.D., Takaomi Ishida, Ph.D., Kazuo Umezawa, Ph.D., Arinobu Tojo, M.D., Ph.D.

Blood (2007) 110 (11): 723.

https://doi.org/10.1182/blood.V110.11.723.723

Published: 2007

Journal Articles

Chemosensitization of CDDP-Resistant Multiple Myeloma Cell Lines Following Treatment with Anti-TfR IgG3-Av.

Eriko Suzuki, Xiao-Ho Gan, MD, Kazuo Umezawa, PhD, Gustavo Helguera, PhD, Gary Schiller, MD, Manuel Penichet, MD, PhD, Benjamin Bonavida, PhD

Blood (2005) 106 (11): 5119.

https://doi.org/10.1182/blood.V106.11.5119.5119

Published: 2005

Journal Articles

Dual targeting of transformed and untransformed HTLV-1–infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia

Mariko Watanabe, Takeo Ohsugi, Momoko Shoda, Takaomi Ishida, Shigemi Aizawa, Masae Maruyama-Nagai, Atae Utsunomiya, Shin Koga, Yasuaki Yamada, Shimeru Kamihira, Akihiko Okayama, Hiroshi Kikuchi, Kimiharu Uozumi, Kazunari Yamaguchi, Masaaki Higashihara, Kazuo Umezawa, Toshiki Watanabe, Ryouichi Horie

Blood (2005) 106 (7): 2462–2471.

https://doi.org/10.1182/blood-2004-09-3646

Published: 2005

Includes: Supplemental data

Journal Articles

Targeting NF-κB and Induction of Apoptosis by Dehydroxymethylepoxyquinomicin (DHMEQ) in Multiple Myeloma Cells.

Yoshitaka Miyakawa, MD, Kanoko Kohmura, MD, Kaori Saito, Hiroshi Yoshida, Asako Ikejima, Yutaka Hattori, MD, Yasuyuki Ohnishi, PhD, Masato Nakamura, MD, Yasuo Ikeda, MD, Kazuo Umezawa, PhD, Masahiro Kizaki, MD

Blood (2004) 104 (11): 3393.

https://doi.org/10.1182/blood.V104.11.3393.3393

Published: 2004

NARROW

Potential of NF-κB Inhibition in the Treatment of Chronic Lymphocytic Leukemia

Inhibition of NF-κB Activation Augments the Effect of 5-Azacytidine On Acute Myeloid Leukemia Cell Line

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Inhibition of the Akt Pathway in MM Cell Lines by the Anti-TfR-IgG3-Avidin Fusion Protein (Anti-TfR-IgG3-Av): Role in Chemosensitization to CDDP-Induced Apoptosis

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Tumor Necrosis Factor-α Contributes to Microenvironmental up- Regulation of NF-κB Activity in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Implication for a Novel Therapeutic Target.

Synergy in Apoptosis Is Achieved in B-NHL by the Combination of Rituximab and the Novel Proteasome Inhibitor NPI-0052: Pivotal Role of Induction of the Immune Surveillance Cancer Gene Product RKIP

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Microenvironmental Up-Regulation of NF-kB Activity Via P65-Dependent and Independent Pathways in a Bioimaging Model of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Chemosensitization of CDDP-Resistant Multiple Myeloma Cell Lines Following Treatment with Anti-TfR IgG3-Av.

Dual targeting of transformed and untransformed HTLV-1–infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia

Targeting NF-κB and Induction of Apoptosis by Dehydroxymethylepoxyquinomicin (DHMEQ) in Multiple Myeloma Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only